PLL Therapeutics
- Company typePrivate
- Founded2019
- HeadquartersVillenave-d'ornon, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
PLL Therapeutics firmographics
Firmographics- Name
- PLL Therapeutics
- Legal name
- PLL THERAPEUTICS
- Website
- https://pll-therapeutics.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
PLL Therapeutics industry classification
Industry- Product category
- Neurology Biopharmaceuticals (ALS Therapeutics)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)
- akta.pro secondary industry
- Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)
Keywords
Where PLL Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Villenave-d'ornon
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
PLL Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Development and Licensing: As a clinical-stage biopharmaceutical company, PLL Therapeutics is developing PLL001 for ALS treatment. Revenue will likely come from drug approval and commercialization, with potential for licensing agreements, partnerships with larger pharmaceutical companies, or direct commercialization upon regulatory approval.
- Diagnostic Services: The company offers early-stage and companion diagnostics services using its blood biomarker test. This represents a potential revenue stream from diagnostic testing services.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
PLL Therapeutics product offering
Product offeringCore offering
PLL Therapeutics develops a proprietary Poly-L-Lysine (PLL) polypeptide delivery platform designed to transport therapeutic molecules to gut cells and across the blood–brain barrier. Its lead product candidate, PLL001, is a first-in-class investigational therapy for Amyotrophic Lateral Sclerosis (ALS) targeting the gut–brain axis. The company also offers an early-stage, non-invasive blood biomarker diagnostic test for ALS with reported 92% sensitivity.
Product overview
PLL Therapeutics operates as a biopharmaceutical company with a platform-plus-products model. The core offering is the Polypeptide Delivery Platform, which uses patented Poly-L-Lysine technology to transport active pharmaceutical ingredients to target tissues. The primary product in development is PLL001, a poly-targeted drug therapy for ALS that combines multiple APIs (DP1 and DP2) to restore microbiome function and intestinal permeability. Supporting the therapeutic approach is an early-stage diagnostic service utilizing blood biomarkers for ALS detection. All offerings center on the company's gut-brain axis hypothesis for treating neurodegenerative and autoimmune diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- PLL001 PLL001 is a first-in-class investigational therapy for Amyotrophic Lateral Sclerosis (ALS) that uses the Poly-L-Lysine delivery platform to target the gut–brain axis, aiming to restore intestinal and blood–brain barrier integrity. It is being developed for ALS patients and pharmaceutical licensing partners.
- Poly-L-Lysine (PLL) Polypeptide Delivery Platform Proprietary Poly-L-Lysine (PLL) polypeptide technology platform that enables targeted transport of therapeutic molecules to gut cells and across the blood–brain barrier. It underpins PLL001 and is positioned for licensing to pharmaceutical partners.
- ALS Blood Biomarker Diagnostic Test Non-invasive companion diagnostic blood test for ALS with reported 92% sensitivity, intended to support early detection and patient stratification in clinical and commercial settings.
- DP1 and DP2 (Polypeptide Building Blocks) DP1 and DP2 are the proprietary polypeptide building blocks of the Poly-L-Lysine delivery platform, commercially protected and used to construct PLL Therapeutics' therapeutic candidates.
Quantifiable outcome
- Phase I trial completed with no Serious Adverse Events (SAE) reported and no Treatment Emergent Adverse Events (TEAEs) resulting in study discontinuation
- +3 more outcomes
Companies that use PLL Therapeutics
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
PLL Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
PLL Therapeutics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- Alithia LifesciencescoreAustralian Contract Research Organization (CRO) collaborating with PLL Therapeutics on the Phase I/II clinical trial for PLL001 in ALS patients. Alithia Lifesciences provides clinical research expertise and site management for the multi-stage study conducted across Australian sites.
- CopexiscoreSwiss consultancy firm providing strategic and operational support for PLL Therapeutics' clinical development program. Partnership facilitates international trial coordination and regulatory affairs expertise.
- Monash HealthcoreLargest public hospital in Melbourne, Australia, serving as the lead clinical site for the Phase I/II ALS trial. Enrolled the first patient in April 2025 and conducted Phase I with 12 patients under Prof. Susan Mathers as lead investigator.
- Alfred HealthcoreMajor Australian hospital network participating as a clinical trial site for PLL Therapeutics' Phase I/II ALS study conducted across multiple sites.
- Calvary Health CarecoreAustralian healthcare provider participating as a clinical trial site for PLL Therapeutics' Phase I/II ALS study.
- Wesley Research InstitutecoreAustralian research institute participating as a clinical trial site for PLL Therapeutics' Phase I/II ALS study.
- Pacific Clinical Research Network (PCRN)coreNew Zealand clinical research organization serving as the single site for Phase II trial enrollment in New Zealand. David Tudor Phillips appointed as director of PLL Tx New Zealand to oversee operations.
- Dr. Philippe CorciacorePreeminent ALS researcher appointed to scientific board in June 2025. Head of ALS Reference Centre since 2005, Professor of Neurology since 2010. Presides over French ALS motor neuron study group and FILSLAN network coordination center. Has co-authored over 300 publications on ALS and participates in MinE and PRECISION clinical studies.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
PLL Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
PLL Therapeutics social profiles
Digital presencePLL Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
PLL Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
PLL Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
PLL Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PLL Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PLL Therapeutics
What does PLL Therapeutics do?
PLL Therapeutics develops a proprietary Poly-L-Lysine (PLL) polypeptide delivery platform designed to transport therapeutic molecules to gut cells and across the blood–brain barrier. Its lead product candidate, PLL001, is a first-in-class investigational therapy for Amyotrophic Lateral Sclerosis (ALS) targeting the gut–brain axis. The company also offers an early-stage, non-invasive blood biomarker diagnostic test for ALS with reported 92% sensitivity.
Is PLL Therapeutics a public or private company?
PLL Therapeutics is a private company. It is classified as management employee owned and is currently operating.
When was PLL Therapeutics founded?
PLL Therapeutics was founded in 2019. It employs 1 to 10 people.
Where is PLL Therapeutics based?
PLL Therapeutics is headquartered in Villenave-d'ornon, France, in the Europe region.
How does PLL Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Development and Licensing is the primary driver. The others are diagnostic Services.
Does PLL Therapeutics have an API?
No public API is recorded for PLL Therapeutics.
What industry is PLL Therapeutics in?
PLL Therapeutics's product category is Neurology Biopharmaceuticals (ALS Therapeutics). Its primary akta.pro industry code is HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays, with a secondary code of HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy). Its NAICS code is 541714 and its SIC code is 2834.